Indeed, GR signalling has been shown to negatively impact ovarian cancer disease outcomes by promoting ROR-1 induced stemness and inducing taxane resistance, a mainstay of ovarian cancer treatment [67]. This evidence concerns the gene NR3C1 and ovarian cancer.